Skip to Content

Steris PLC STE

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Narrow-Moat Steris Reports Decent Growth and Record Margin in Fiscal Q3 With Cantel Purchase Pending

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Narrow-moat Steris reported decent fiscal third-quarter results that met expectations. We had previously updated our model to account for the pending Cantel Medical acquisition, and we are leaving our $181 fair value estimate unchanged. Shares remain fairly valued following the decline in the stock price at market open, which we attribute to Steris’ announcement of CEO Walt Rosebrough’s retirement.

Read Full Analysis

Company Profile

Business Description

Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.

70 Sir John Rogerson's Quay
Dublin, D02 R296, Ireland
T +353 12322000
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Dec 31, 2020
Fiscal Year End Mar 31, 2021
Stock Type
Employees 13,000